Form 4: United Therapeutics CFO James Edgemond Executes Stock Options and Sells Shares Under 10b5-1 Plan

James Edgemond, CFO and Treasurer of United Therapeutics, exercised stock options and sold shares of common stock on October 21, 2024, according to a Form 4 filing with the SEC.

Summary

• On October 21, 2024, James Edgemond, the CFO and Treasurer of United Therapeutics Corp, executed stock options and sold shares of the company's common stock.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on May 17, 2024.
• Edgemond exercised options to acquire a total of 8,334 shares at exercise prices of $120.26 and $117.76.
• Simultaneously, he sold a total of 4,882 shares at a price of $366.99 per share.
• Some of the option exercises were 'sell-to-cover' transactions, where a portion of the shares acquired were immediately sold to cover the exercise cost.
• Following these transactions, Edgemond directly owns 6,978 shares of common stock.
• He also holds options for 249,003 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing plan. It doesn't inherently indicate positive or negative news about the company.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The use of a 10b5-1 plan indicates that these transactions were pre-planned and not based on any inside information at the time of the trades.

Comparison to Industry Standards

• Executive compensation packages often include stock options to align management's interests with those of shareholders.
• The use of 10b5-1 trading plans is a common practice among corporate executives to avoid accusations of insider trading.
• Comparable companies in the biotechnology or pharmaceutical sectors, such as Amgen (AMGN) or Gilead Sciences (GILD), also see regular Form 4 filings from their executives.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature of the trades mitigates concerns about insider information.

Key Dates